Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Prices $5.7B Senior Notes Offering

NEW YORK – Thermo Fisher Scientific today priced an underwritten offering of a series of euro- and dollar-denominated senior notes, in an aggregate principal amount of $5.7 billion.

The firm priced €800 million ($877.8 million) aggregate principal amount of its 0.125 percent senior notes due 2025; €800 million aggregate principal amount of its 0.5 percent senior notes due 2028; €900 million aggregate principal amount of its 0.875 percent senior notes due 2031; €900 million aggregate principal amount of its 1.5 percent senior notes due 2039; €1.0 billion aggregate principal amount of its 1.875 percent senior notes due 2049; and $900 million aggregate principal amount of its 2.6 percent senior notes due 2029.

Waltham, Massachusetts-based Thermo Fisher will use the funds to redeem two classes of senior notes with a total aggregate principal of $1.1 billion, as announced earlier this month.

Thermo Fisher will also use the funds to redeem $4.5 billion aggregate principal amount of outstanding senior notes issued by the firm or its subsidiaries, including all outstanding 6 percent senior notes due 2020 and 5 percent senior notes due 2021 issued by its Life Technologies subsidiary.

The joint book-running managers for the euro offering are Goldman Sachs, Merrill Lynch International, Citigroup Global Markets and JP Morgan. The joint book-running managers for the dollar-denominated offering are Goldman Sachs, Bank of America Securities, Credit Suisse Securities, and HSBC Securities.

The euro offering is expected to close on or about Sept. 30, and the dollar-denominated offering is expected to close on or about Oct. 8. The euro notes will pay interest on an annual basis, while the dollar-denominated notes will pay interest on a semi-annual basis.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.